All lecturesID Practice Update

Resident and fellow education

Nontuberculous Mycobacterial Infections

Pulmonary disease, extrapulmonary infection and the decisions that change treatment.

Resident coreOptional fellow sectionEdited November 10, 2026

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.

Determine whether the isolate is causing disease

Resident core

Decide whether NTM is causing disease, whether to treat, which species-specific regimen is appropriate, and how to follow efficacy and toxicity.

Advanced teaching

Resistance, treatment failure, mixed isolates, organ dysfunction, surgery, drug levels and newer evidence.

Jump to fellow section

The main pulmonary recommendations follow the 2020 multisociety guideline for adults without HIV or cystic fibrosis. HIV-associated and CF-associated NTM require their own guidance and specialist assessment. Skin, bone, joint, device and disseminated infections require different specimens, source control and treatment endpoints.

HIV-associated disseminated MAC and TB   |   TB treatment module

An AFB-positive smear does not distinguish NTM from tuberculosis. Use the TB diagnostic and airborne-precaution pathway when pulmonary TB remains plausible. Do not give a partial TB regimen while assuming the isolate is NTM.

Sources [1] [13]

Establish clinical, radiographic and microbiologic evidence

Clinical illness

Chronic cough, sputum, fatigue, weight loss, hemoptysis or impaired function. Identify which symptoms could instead reflect bronchiectasis, aspiration or another infection.

Compatible imaging

Nodular-bronchiectatic disease with small nodules or tree-in-bud changes, or fibrocavitary disease. Neither pattern is specific for NTM.

Microbiologic confirmation

Usually at least two separate sputum cultures with the same species, or one positive bronchial wash/BAL. M. abscessus requires agreement at the subspecies level.

Obtain at least three respiratory samples over at least a week when evaluating chronic NTM disease. Use induced sputum if needed; bronchoscopy is usually reserved for patients unable to produce specimens despite induction. Biopsy can meet criteria when mycobacterial histologic features are accompanied by a positive tissue culture, or by a positive respiratory culture. Exclude competing diagnoses.

Ask the laboratory for species identification, clinically relevant susceptibilities and M. abscessus subspeciation. A negative smear does not exclude disease. IGRA is not an NTM diagnostic test; some species, including M. kansasii and M. marinum, can cross-react.

The species changes the meaning of a positive culture
FindingInterpretation and next step
One sputum culture with MAC, mild symptoms and stable CTRepeat cultures and assess competing causes before committing to prolonged therapy.
Repeated MAC isolation with progressive cavities and smear positivityHigh concern for clinically important disease. Arrange treatment promptly after baseline testing.
M. kansasii in a compatible cavitary syndromeMore pathogenic than many other NTM. A single isolate may be sufficient in the right context; do not apply the MAC single-isolate rule mechanically.
M. gordonae in one respiratory specimenOften contamination or transient isolation. Require unusually convincing repeated microbiology and clinical evidence before attributing disease.

Sources [1] [8]

Some respiratory NTM isolates are much less likely to represent disease

Contamination means the organism entered the specimen during collection, processing or bronchoscopy. Transient respiratory isolation means it was recovered from the airway without established disease. Neither can always be distinguished from early infection on the first culture. Document "NTM isolated; pulmonary disease not established" when that is what the evidence supports.

Interpretation applies to sputum and BAL, not automatically to other sites
OrganismUsual respiratory interpretationImportant exception or next step
M. gordonaeClassic low-pathogenicity, water-associated contaminant. A single isolate rarely explains pulmonary illness.Require repeated recovery and strong clinical/radiographic evidence before attributing disease. Rare true infection occurs, including in immunocompromised patients.
M. mucogenicumRespiratory recovery is usually contamination or otherwise clinically insignificant.This interpretation does not apply to blood or catheter cultures, where it is a recognized pathogen.
M. terrae complexUsually a contaminant in respiratory specimens; pulmonary disease is uncommon.Confirm identification and corroborating evidence. Members of this group can cause genuine tenosynovitis and other deep infections.
M. fortuitum complexLower pulmonary pathogenicity than the major pulmonary NTM; an isolated culture may not represent disease.Persistent isolation with compatible disease needs evaluation. Do not dismiss wound, device or deep-tissue isolates using the respiratory interpretation.
MAC or M. abscessus complexEstablished pulmonary pathogens, but recovery alone is insufficient to diagnose disease.Apply the clinical, imaging and microbiologic criteria. An isolated MAC sputum culture often warrants repeat sampling before treatment.
M. kansasiiHigher concern for true disease in a compatible syndrome.A single positive culture may be clinically meaningful. Do not group it with the usual low-pathogenicity contaminants.

These are probability judgments, not a list of organisms that can never cause infection. Species identification, immune status and geographic epidemiology matter. Published respiratory cohorts support particularly low clinical relevance for M. gordonae and M. mucogenicum; their proportions are not universal diagnostic cutoffs.

Sources [1] [8] [15]

One positive BAL meets the microbiologic criterion, not the entire diagnosis

Compatible symptoms and imaging, exclusion of alternative explanations, and assessment of the species are still required. BAL is not immune to contamination. A low-pathogenicity organism from one BAL should not trigger treatment simply because the specimen came from bronchoscopy.

For a stable patient with a discordant result, review prior cultures and CT evolution, confirm the identification with microbiology, and obtain separate expectorated or induced sputum samples when feasible. Do not repeat bronchoscopy solely to satisfy a culture count when less invasive sampling is available. Progressive disease or substantial immune suppression warrants more urgent assessment.

Sources [1] [15]

Look for a collection or bronchoscopy problem when results cluster

Tap water, rinse water and contaminated bronchoscopy equipment can produce false-positive respiratory cultures. CDC describes bronchoscopy-associated pseudo-outbreaks involving M. gordonae, M. chelonae and M. xenopi. The latter two can also cause real disease; a reported pseudo-outbreak association does not make every isolate a contaminant.

If several patients have an unexpected species after a shared procedure, or microbiology conflicts sharply with the clinical findings, involve microbiology and infection prevention. Review collection technique, water exposure, procedure dates and equipment/reprocessing records. A pseudo-outbreak is a cluster of positive results without corresponding infection; procedural contamination can also cause true infection, so assess each patient.

Sources [16] [17]

M. gordonae from BAL during a malignancy workup

A patient with a solitary lung mass has one smear-negative BAL culture growing M. gordonae, without a compatible diffuse nodular-bronchiectatic or cavitary syndrome.

The culture does not establish NTM disease or explain the mass. Continue the mass evaluation, review collection/procedure concerns and obtain follow-up respiratory cultures if clinically indicated. Avoid starting an NTM regimen on this result alone.

Choose treatment or structured observation with the patient

Factors favoring treatment

Cavitation, positive AFB smears, radiographic progression, substantial symptoms or weight loss, extensive disease, immune suppression, and a more pathogenic or treatable species.

Factors favoring observation

Mild stable noncavitary disease, uncertain attribution of symptoms, high toxicity risk and patient preference. Meeting diagnostic criteria alone does not mandate antibiotics.

Observation needs an explicit plan for longitudinal assessment of symptoms, cultures and imaging. Individualize follow-up and document the findings that would trigger treatment.

Treat the underlying lung disease in either pathway

Arrange individualized airway clearance with respiratory therapy, exercise as tolerated, nutritional assessment and smoking cessation. Assess aspiration or reflux when suggested by the history. Review the indication for corticosteroids and other immunosuppression. Consider an underlying bronchiectasis cause, including immune deficiency or CF when the phenotype warrants it.

Avoid macrolide monotherapy for bronchiectasis in someone with potentially active MAC or M. abscessus disease. It can select resistance to a key treatment drug.

Airway clearance and nutrition are supportive care. Observational associations do not prove they prevent NTM recurrence or replace antibiotics in progressive disease.

Sources [1] [2] [14]

MAC treatment depends on severity and macrolide susceptibility

Start with the pulmonary MAC phenotype
Pulmonary MAC phenotypeInitial approachDuration and reassessment
Macrolide-susceptible, noncavitary nodular-bronchiectatic disease without advanced severityAzithromycin + ethambutol + rifampin, three times weekly. Daily treatment is also used when the clinical situation warrants it.For macrolide-susceptible MAC, treatment extends at least 12 months beyond sputum culture conversion. This clock starts at the first negative culture in the sustained series.
Cavitary or advanced/severe bronchiectatic diseaseFor susceptible MAC, cavitation or advanced bronchiectatic disease favors daily azithromycin, ethambutol and rifampin. The guideline suggests adding parenteral amikacin or streptomycin initially, typically for at least 2 to 3 months, when toxicity risk permits.Serial cultures establish conversion. The same post-conversion duration applies; response and toxicity guide the parenteral phase.
Persistent positive cultures after at least 6 months of an adequate regimenPersistent cultures raise questions about adherence, exposure and resistance. Amikacin liposome inhalation suspension (ALIS) is an add-on option for eligible adults.The US indication is limited to adults with few or no alternatives whose sputum remains culture-positive after at least six consecutive months of multidrug therapy. ALIS is added to active companion drugs; nebulized parenteral amikacin is a different formulation.
Macrolide-resistant MACObtain expert consultation and rebuild a multidrug regimen, often including parenteral amikacin when active. Consider resection for selected localized disease.Do not count the macrolide as active or simply add one oral drug to a failing regimen.

Azithromycin is generally preferred over clarithromycin for tolerability and fewer interactions. Ethambutol is particularly important for protecting the macrolide from acquired resistance. If ethambutol must stop, redesign the regimen before allowing prolonged inadequate companion therapy.

Test macrolide and amikacin susceptibility. Do not treat every reported MIC as equally predictive of MAC treatment response.

Sources [1] [4]

Why each drug is in the MAC regimen
DrugRoleIf treatment is interrupted
AzithromycinThe principal active oral agent for macrolide-susceptible MAC.Confirm susceptibility if cultures remain positive or recur. Avoid macrolide monotherapy.
EthambutolHelps prevent acquired macrolide resistance.If visual toxicity is suspected, hold ethambutol and reassess the remaining regimen promptly.
RifampinUsual third agent; a rifamycin can create major drug interactions.Review whether rifabutin or another third drug is feasible before dropping a companion.

A switch from daily to intermittent therapy depends on phenotype and susceptibility. It is inappropriate for cavitary or advanced disease.

Sources [3]

When a rifamycin is difficult to use

A small open-label trial found sputum conversion in 55.0% with clarithromycin and ethambutol and 40.6% when rifampin was added. Drug exposures and sample size limit interpretation. An uncontrolled cohort reported microbiologic cure in 72 of 108 patients who completed at least 12 months on two drugs. Among 18 nonconverters with paired isolates, two developed macrolide resistance.

MAC2v3 randomized previously untreated patients with noncavitary pulmonary MAC to intermittent azithromycin and ethambutol with or without rifampin. In the 2026 published meeting abstract, the two-drug arm was better tolerated. The per-protocol analysis counting treatment intensification as failure estimated a difference in culture negativity at 12 months of −5.0 percentage points (95% CI, −15.5 to 5.1). The interval crossed the prespecified −10-point margin. Noninferiority and equivalent protection against macrolide resistance were not established.

The 2020 guideline suggests at least three drugs, including a macrolide and ethambutol; this is a conditional recommendation based on very low-certainty evidence. The role of the third drug in preventing acquired macrolide resistance remains an important uncertainty. In selected macrolide-susceptible, noncavitary disease with rifamycin intolerance or interactions, discuss two drugs with an NTM specialist, alongside a clofazimine-containing three-drug alternative. Do not extrapolate these findings to cavitary/severe or macrolide-resistant disease, or to disseminated HIV-associated MAC. Maintain ethambutol, serial cultures and reassessment for resistance if response fails.

Sources [1] [6] [18] [19] [25]

M. abscessus requires subspecies and resistance interpretation

M. abscessus complex includes subspecies abscessus, massiliense and bolletii. Subspecies massiliense usually has a nonfunctional erm(41) gene and is more likely to retain macrolide activity. Subspecies identification alone cannot exclude acquired resistance.

A preliminary susceptible result may change
Laboratory resultWhat it meansTreatment implication
Macrolide susceptible early, resistant after extended incubationInducible resistance, usually from functional erm(41).Do not count azithromycin or clarithromycin as active.
Macrolide resistant early, or resistance-associated rrl mutationConstitutive/acquired resistance.Macrolide is not an active component even if the subspecies is massiliense.
No inducible or mutational resistanceMacrolide activity is retained.Include a macrolide in the active multidrug regimen.

Ask for extended macrolide testing, generally through 14 days, and/or molecular assessment of erm(41), plus evaluation for mutational resistance. Test amikacin and the other candidate drugs using a reference laboratory when needed.

The initial phase typically combines IV agents with oral companions. The 2020 guideline suggests at least three active drugs in the initial phase (Question XX, conditional, very low certainty). Its treatment summary suggests at least four active drugs when feasible for inducible or mutational macrolide resistance. An inactive macrolide does not count toward that total. IV amikacin, imipenem or cefoxitin, and tigecycline are common options; oral choices may include clofazimine or linezolid. Selection depends on susceptibility, exposure and tolerability.

After the IV phase, continuation therapy usually retains at least two to three active agents, sometimes including inhaled amikacin. Neither the IV-phase length nor the total treatment duration has a well-established universal standard. Plan both with an NTM specialist. The MAC post-conversion duration does not apply.

A macrolide sometimes remains in a resistant M. abscessus regimen for immunomodulation. It does not count toward the active-drug total. Monitor for other NTM species that could acquire resistance during that exposure.

Sources [1] [14]

M. abscessus regimen examples

These examples assume amikacin susceptibility. Build the regimen with an NTM specialist, using the isolate’s resistance mechanism, likely drug activity and what the patient can tolerate. See drug selection and toxicity.

M. abscessus combination examples
Resistance patternInitial IV-containing phaseContinuation options
Macrolide active: no inducible or mutational resistanceAzithromycin + IV amikacin + imipenem (or cefoxitin) + clofazimine is one framework. Target at least 3 active agents. Tigecycline or linezolid may replace or supplement a poorly tolerated or unsuitable component.Azithromycin + clofazimine + inhaled amikacin is one possible framework. Linezolid is another companion option. Retain at least 2-3 active drugs.
Inducible or mutational macrolide resistanceIV amikacin + imipenem (or cefoxitin) + tigecycline + clofazimine is one framework, aiming for at least 4 active agents when possible. Linezolid may be an additional or substitute companion if activity and tolerability support it.Clofazimine + linezolid + inhaled amikacin may be feasible if sufficiently active and tolerated. If this leaves too few active drugs, revise or continue IV therapy rather than force an inadequate oral/inhaled phase.

A retained macrolide in resistant disease is for immunomodulation and does not count as active. Clofazimine, tigecycline and omadacycline MICs lack validated clinical breakpoints; beta-lactam and linezolid MICs also have limited outcome correlation. Interpret the whole regimen with an experienced laboratory and NTM clinician. Imipenem and cefoxitin are alternatives, not routinely a dual-beta-lactam combination.

Oral omadacycline is an off-label option when a tetracycline component is needed and prolonged IV tigecycline is impractical or intolerable. A short placebo-controlled trial did not establish equivalence to tigecycline or the optimal duration of combination therapy.

Sources [1], Table 5 [3] [7]

Other species require distinct treatment decisions

Recognize the species before extrapolating a regimen
SpeciesTypical clinical settingTreatment approach and pitfall
M. kansasiiCavitary lung disease, often with structural lung disease.Rifampin-susceptible disease usually responds to rifampin, ethambutol and either isoniazid or a macrolide. Treatment lasts at least 12 months total, measured from the start of therapy. Cultures still positive at month four warrant expert reassessment.
M. xenopiPulmonary disease that may be cavitary and severe.A daily regimen includes rifampin, ethambutol and a macrolide, moxifloxacin or both. Severe disease may justify initial parenteral amikacin. Treatment extends at least 12 months after culture conversion.
M. fortuitum complexPostprocedural wounds, device infections and occasional lung disease.Significant infection generally requires at least two drugs active against the isolate. Options include a fluoroquinolone, TMP-SMX, doxycycline or amikacin. Do not assume macrolide activity; inducible resistance is important.
M. chelonaeSkin nodules or disseminated skin disease, particularly with immunosuppression.A susceptible macrolide is often central, with additional active therapy for serious disease. Tobramycin can be more active than amikacin; cefoxitin is generally unreliable. Newly described erm(55) means inducible macrolide resistance cannot be categorically excluded.
M. marinumAquatic inoculation, sporotrichoid skin lesions, tenosynovitis.For more than minimal disease, a macrolide + ethambutol is a common combination; deeper disease may need rifampin and surgery. See extrapulmonary section.
M. chimaeraA MAC member causing lung disease; also invasive infection after cardiac surgery.Pulmonary disease follows MAC principles. Prosthetic cardiovascular infection requires a separate source-control and dissemination evaluation.

For M. kansasii, test rifampin susceptibility. Daily therapy is used for cavitary disease and for isoniazid-containing regimens. A macrolide-containing regimen may be intermittent for selected noncavitary disease. Pyridoxine accompanies isoniazid. Pyrazinamide has no role. If rifampin resistance or intolerance prevents a standard regimen, obtain expert advice rather than treating as drug-susceptible TB.

Sources [1] [8] [10] [12]

Follow symptoms, cultures and toxicity separately

Before treatment, record weight, functional limitations, sputum burden, CT findings and baseline cultures. Obtain CBC, creatinine/electrolytes and hepatic tests. Add ECG, visual acuity/color testing and audiometry according to the planned drugs. Reconcile all medications and supplements.

How findings during treatment change care
WhenWhat to reviewWhat the result should change
Clinical follow-upWeight, respiratory symptoms, appetite, nausea, diarrhea, missed doses, airway clearance and patient goals. Add drug-specific questions: hearing/balance with ototoxic agents; vision with ethambutol or linezolid; neuropathy with linezolid or isoniazid.Address intolerance early. New symptoms may reflect drug injury, bronchiectasis or coinfection rather than NTM progression.
During IV treatmentCBC, liver tests, renal function and electrolytes help detect toxicity. IV amikacin also warrants timed concentrations and close hearing and balance surveillance.Change doses or intervals for evolving organ dysfunction. Do not wait for the next scheduled visit if toxicity develops.
During stable oral treatmentSerial blood counts, renal function, electrolytes and hepatic tests can identify toxicity before symptoms develop. The regimen, prior results and new symptoms determine when to reassess.Individualize to the drug combination. Linezolid in particular can suppress the marrow.
Microbiologic response during treatmentDuring pulmonary MAC treatment, sputum cultures roughly monthly help establish when conversion occurs. Induced sputum can be useful when the patient cannot expectorate.Date conversion from the first negative in a sustained series. A single negative sample is insufficient.
At clinical milestonesUse clinical, radiographic and microbiologic findings together to assess response. Imaging helps when the course suggests progression or symptoms and cultures disagree.CT improvement supports response but does not replace cultures or establish microbiologic cure.
After completing treatmentSerial cultures during the first year after treatment can detect recurrence. New symptoms warrant earlier reassessment.Re-identify recurrent isolates and consider new infection as well as relapse.

Monitoring intervals are largely expert practice and should be intensified for renal disease, frailty, overlapping toxicities or abnormal results. The NTM-NET consensus dates conversion to the first of at least three consecutive negative respiratory cultures collected at least four weeks apart during therapy. Persistent sputum negativity does not mean bronchiectasis symptoms will disappear.

Sources [1] [2] [3] [28]

Symptoms that require prompt assessment

Toxicity surveillance is part of treatment delivery
Drug or classProblem to anticipateResponse
EthambutolBlurred vision, reduced color discrimination or central visual change. Renal impairment increases exposure.Assess visual acuity and color discrimination before treatment and periodically during therapy, with frequency individualized to risk. New visual symptoms require holding ethambutol and urgent assessment.
IV or inhaled amikacinTinnitus, hearing loss, imbalance; kidney injury. Inhaled treatment can cause dysphonia, cough, bronchospasm or hemoptysis. ALIS also carries a boxed warning for serious respiratory reactions, including hypersensitivity pneumonitis and exacerbation of underlying lung disease.Obtain baseline audiometry and repeat during therapy according to risk and symptoms. New tinnitus, hearing loss or vestibular symptoms warrant holding the aminoglycoside and contacting the treating team promptly, even if creatinine is normal. Discontinue ALIS and assess promptly if hypersensitivity pneumonitis or anaphylaxis occurs; evaluate new respiratory deterioration before attributing it to NTM progression.
Macrolides, clofazimine, moxifloxacin, bedaquilineQT prolongation, additive interactions and gastrointestinal intolerance. Macrolides can also cause hearing loss; ask about hearing symptoms and use audiometry according to exposure, symptoms and risk.Review ECG and K/Mg before combining agents; reassess with changes in therapy, electrolyte losses or new symptoms. Clofazimine and bedaquiline need ongoing monitoring as exposure accumulates.
Rifampin or rifabutinHepatic injury, cytopenias and major interactions; rifabutin can cause uveitis.Review anticoagulants, ART, transplant immunosuppression and azole antifungals. Anticipate interaction changes when starting and stopping the rifamycin.
LinezolidCytopenias, peripheral/optic neuropathy, lactic acidosis and serotonergic interactions.Monitor CBC weekly throughout treatment. New visual symptoms warrant prompt ophthalmic evaluation at any point; monitor visual function with prolonged exposure and ask about peripheral neuropathy. Consider linezolid drug levels to identify excessive exposure and guide dose reduction while preserving regimen activity. Persistent nausea or unexplained acidosis needs assessment, not just an antiemetic.
Tigecycline or omadacyclineNausea, poor intake and weight loss; hepatic abnormalities. Tigecycline can cause pancreatitis.Track weight and intake, not laboratory results alone. Reassess severe abdominal symptoms. Oral omadacycline requires careful fasting and cation separation.
Cefoxitin or imipenemCytopenias, hepatic abnormalities and renal-dose issues; imipenem can cause neurotoxicity.Follow blood counts, hepatic and renal function. Investigate confusion or myoclonus.
Do not leave the patient taking only the easiest drug while stopping the rest. A serious adverse reaction may require a coordinated interruption and reconstruction of the full regimen. Prolonged unplanned monotherapy can sacrifice future treatment options.

Sources [1] [3] [4] [2] [27]

Outside the lung, tissue diagnosis and source control become central

Obtain deep tissue or aspirate for mycobacterial culture and histopathology; superficial swabs are less useful. Send a separate unfixed specimen for culture, not only tissue in formalin. Tell the laboratory about water exposure and suspected species because special growth conditions may be needed. Negative AFB stains do not exclude infection.

Match the specimen and endpoint to the site
SyndromeWorkupManagement
Postoperative, injection-associated or cosmetic-procedure infectionConsider rapid growers when nodules, draining sinuses or abscesses persist despite usual antibiotics. Obtain deep specimens and assess retained foreign material.Drain/debride and remove infected material when feasible. Use species- and susceptibility-directed combination therapy. Significant rapid-grower skin disease commonly needs months of treatment, often around 4-6 months, individualized to depth and source control.
Aquarium-associated hand lesion or tenosynovitisSuspect M. marinum; request lower-temperature culture. Assess tendon sheath, joint and bone involvement.Macrolide + ethambutol is a common approach; deep infection may require rifampin and operative debridement. Continue treatment 1-2 months beyond clinical resolution; deep disease needs longer than a superficial lesion.
Osteomyelitis, septic arthritis or hardware infectionObtain multiple operative specimens and assess implant involvement. Identify the species before selecting a long regimen.Combine surgery with active drugs; courses often last 6-12 months or longer. This is low-quality, species-dependent evidence, not a universal duration. Hardware retention can limit cure.
Cervical lymphadenitis, especially in childrenObtain tissue diagnosis and distinguish TB, malignancy and bacterial adenitis.Complete excision may be curative for localized NTM lymphadenitis. Involve ENT because facial nerve injury and fistula risk affect the decision; medical treatment is individualized.
Catheter-associated bloodstream infectionRapid growers should not automatically be dismissed as contaminants. Repeat cultures, identify the species and look for metastatic sites if persistent.Remove the implicated catheter when feasible and use active systemic therapy. Duration depends on species, clearance and complications; do not apply a short routine bacterial line-infection course reflexively.
Disseminated disease or prosthetic cardiovascular infectionObtain mycobacterial blood cultures and involved-tissue samples. Assess HIV, immunosuppression and organ involvement. Prior cardiac surgery raises concern for M. chimaera.Specialist combination therapy plus source control where possible. Involve cardiac surgery for infected prosthetic material and infection prevention for a possible healthcare-associated exposure.

For advanced HIV, see the disseminated MAC section and prophylaxis section. Disseminated MAC uses a macrolide plus ethambutol, with additional therapy for selected severe disease and prompt ART. Treatment completion depends on clinical response and immune recovery, not the pulmonary sputum-conversion clock.

Sources [8] [9] [13] [11] [12]

Clinical cases

One positive MAC culture

A patient with mild bronchiectasis has stable weight and CT findings, and MAC in one of three sputum cultures.

Repeat cultures, optimize airway clearance and look for other causes of symptoms. The current evidence does not justify committing to prolonged MAC therapy solely on that result.

Still culture-positive at month seven

A patient taking daily MAC treatment reports missing ethambutol most days because of visual concerns.

New visual symptoms warrant holding ethambutol and urgent eye assessment. Reconstruct the drugs actually taken and repeat susceptibility testing. Seven months elapsed does not establish six consecutive months of adequate multidrug treatment; ALIS cannot compensate for ineffective companion therapy.

A susceptibility result changes

M. abscessus is clarithromycin-susceptible at the early reading and resistant at day 14.

This is inducible resistance. The macrolide cannot be counted as active. Rebuild the active-drug count with expert input before proceeding.

Sources [1]

Complex disease starts with a reassessment of the diagnosis

Optional fellow section

Before escalating, reconstruct the course from culture dates, species, smear burden, CT changes, actual doses and interruptions. Review absorption, access, interactions and whether the patient is taking the intended regimen.

Persistent symptoms are not synonymous with persistent NTM

Evaluate bacterial bronchiectasis exacerbation, aspiration, malignancy, drug toxicity and Aspergillus-related disease when suggested by the presentation. Aspergillus isolation or BAL galactomannan alone does not establish chronic pulmonary aspergillosis or ABPA. Use the appropriate clinical, radiographic and immunologic criteria. Rifamycins can make azole treatment ineffective.

Mixed MAC and M. abscessus cultures

Identify each isolate and reassess whether it meets criteria for clinically significant disease. The pulmonary NTM guideline advises surveillance for other NTM species during treatment, particularly when a macrolide is used for immunomodulation in macrolide-resistant M. abscessus disease. Concurrent disease warrants expert consultation.

Macrolide activity must be interpreted for each organism. Do not count a macrolide as active against an inducibly or mutationally resistant M. abscessus isolate.

Recurrence after apparent cure

Reculture and repeat species identification and relevant susceptibility testing. Reinfection with a new strain is common in structural lung disease; recurrence does not prove nonadherence or inadequate prior duration. Distinguishing same-species relapse from reinfection can require comparison of stored isolates with molecular typing.

Sources [1] [2]

Drug selection, interactions and toxicity

When an adverse effect or interaction removes a drug, reassess how many active agents remain and which drug they protect. Renal dysfunction, hepatic disease, pregnancy and dialysis can change the choice of regimen.

Choosing and retaining active drugs
DrugRoleWhat may change the choice
Azithromycin or clarithromycinMacrolide activity is central to susceptible pulmonary MAC.Azithromycin usually has fewer interactions. Check other QT-prolonging drugs and ask about hearing changes.
EthambutolCompanion to the macrolide in susceptible MAC.Renal impairment increases exposure. New changes in acuity or color vision warrant holding ethambutol and urgent assessment.
Rifampin or rifabutinRifampin is the usual third drug for susceptible MAC; rifabutin is an option when interactions limit rifampin.Both can interact with antiretrovirals and transplant drugs. Rifabutin can cause uveitis and cytopenias.
ClofazimineA possible alternative to rifampin in selected MAC regimens and a companion drug for M. abscessus.Discuss pigmentation and gastrointestinal effects, review QT risk and establish access before relying on it.
IV amikacinInitial intensification for selected severe disease, when the isolate is susceptible.Use renal function, timed serum concentrations and audiometry to assess exposure and injury. Vestibular or auditory injury can occur despite stable creatinine.
Imipenem or cefoxitinAlternative IV beta-lactams for the initial phase of M. abscessus treatment.Renal impairment alters exposure. Confusion or myoclonus can signal imipenem toxicity; cytopenias can limit prolonged cefoxitin use.
TigecyclineAn IV option for M. abscessus.Nausea and weight loss can make treatment unsustainable. Severe abdominal pain warrants evaluation for pancreatitis.
LinezolidAn oral or IV companion in selected regimens.Marrow suppression, optic or peripheral neuropathy and interacting serotonergic drugs may limit use. A low trough does not exclude toxicity.
OmadacyclineAn off-label companion for selected M. abscessus infections.Food, dairy and polyvalent cations can reduce oral absorption. Its equivalence to IV tigecycline has not been established.
Inhaled amikacinLiposomal amikacin (ALIS) has a limited US indication for refractory pulmonary MAC. Nebulized parenteral amikacin is off-label.The two formulations are not interchangeable. ALIS requires its dedicated nebulizer, is contraindicated in patients with known hypersensitivity to any aminoglycoside, and can cause serious respiratory reactions.
MoxifloxacinAn option in a multidrug regimen for M. xenopi.Review cumulative QT risk and cations that impair oral absorption.
IsoniazidAn alternative to a macrolide alongside rifampin and ethambutol for rifampin-susceptible M. kansasii.Use pyridoxine and monitor for liver injury and neuropathy.

Sources [1], Tables 3 and 5 [3] [4] [23].

Drug levels answer specific exposure and toxicity questions

Routine TDM is most established for IV aminoglycosides. For oral drugs, consider it when poor response, malabsorption, major interactions or toxicity raises a specific question. A target concentration is not a guarantee of cure.

Use drug levels with a defined clinical question
SituationPractical interpretation
IV amikacinAn individualized pharmacokinetic assessment relates drug exposure to renal clearance, cumulative treatment and toxicity risk.
Amikacin concentrationsFor parenteral amikacin, reference peaks are 35–45 mcg/mL with daily therapy and 65–80 mcg/mL with intermittent therapy. The guideline lists a trough below 5 mg/L. Interpret the value against the actual regimen, collection time and the method used to estimate the peak.
Timing of amikacin levelsEstimating a peak may require more than one postinfusion sample. The infusion and collection times determine whether a reported concentration can be compared with a peak or trough.
Long-term linezolidA correctly timed predose concentration can help explain toxicity during prolonged use, particularly with renal dysfunction or cytopenias. A trough below 2 mg/L has been proposed as a safety goal; the strongest clinical exposure-toxicity data cited here come from TB. This is neither an NTM efficacy target nor a guarantee against injury. Interpret the result alongside symptoms, CBC, susceptibility and companion drugs.
Selected oral-agent TDMConsider for unexpected failure or absorption/interactions. A low early level may reflect delayed absorption; paired later sampling can help. Coordinate assay availability and interpretation before ordering.

For ethambutol, impaired renal clearance may require a longer interval. For IV amikacin, a lower dose, a longer interval or both may be appropriate; renal function and timed concentrations guide the choice. Rifampin affects anticoagulants, ART and transplant medications. Rifabutin has fewer induction effects but is not interaction-free. QT-active combinations require an individualized ECG and electrolyte plan.

Sources [1] [3]

When a level is sent to a reference laboratory

The sample type and timing must match the clinical question. For send-out testing, the performing laboratory’s current instructions govern collection and handling.

Public reference-laboratory options for linezolid TDM
LaboratoryTest and ordering resourceCollection planning
National Jewish Health, Advanced Diagnostic LaboratoriesLinezolid level: PKLZD; current test instructions.Check the performing laboratory’s specimen, processing and transport requirements before collection.
University of Florida, Infectious Disease Pharmacokinetics Laboratory (IDPL)Linezolid: LNZL. Current catalog and requisition.Confirm assay-specific volume and current collection/shipping requirements. The catalog includes other antimycobacterial drug assays.

Specify whether the question is a trough or postdose exposure profile. Include exact dose, dosing interval, last administration time, infusion times if applicable, sample time, renal function and relevant MIC. Do not send an untimed “random” linezolid level and interpret it as a trough. Send-out turnaround does not replace prompt action for suspected serious toxicity.

Sources [24] [20] [21] [22]

Salvage treatment requires evidence and realistic goals

Evidence for selected treatment options
OptionWhat supports itLimit of the evidence
ALIS for refractory MACIn CONVERT, culture conversion by month six occurred in 29.0% with ALIS plus background therapy versus 8.9% with background therapy alone.CONVERT enrolled adults with persistent cultures despite multidrug treatment. Serious respiratory toxicity can occur. The June 2026 US label limits ALIS to the refractory MAC population described above; use for M. abscessus is off-label.
ALIS in newly diagnosed pulmonary MACENCORE randomized 425 adults untreated for their current episode to ALIS or inhaled placebo, each with daily azithromycin and ethambutol. Respiratory symptom scores improved 3.11 points more with ALIS at month 13. Culture conversion by month 13, a prespecified secondary endpoint, occurred in 82.4% versus 55.6%.The comparator was azithromycin and ethambutol without a rifamycin. These results do not compare ALIS with standard rifamycin-based triple therapy or extend the current US indication. In September 2026, Insmed reported a January 28, 2027 FDA target action date for its indication expansion application. Check the current FDA label for any subsequent change.
Clofazimine replacing rifampin in MACA small open-label randomized trial enrolled 40 patients. Six-month conversion was 62% with clofazimine and 58% with rifampin, each combined with ethambutol and a macrolide.Useful support for a selected alternative, not proof of universal interchangeability. Diarrhea, pigmentation, QT effects and access matter. Do not extrapolate pulmonary MAC findings to HIV-associated disseminated MAC.
Omadacycline for M. abscessusA 2026 phase 2 trial compared short-term omadacycline monotherapy with placebo in 66 adults. Symptom-response estimates favored omadacycline; nausea and discontinuation remained relevant.Short-term monotherapy research does not establish durable cure or justify routine clinical monotherapy. Use as a specialist-selected off-label component when appropriate.

When to consider pulmonary surgery

Refer selected patients with localized destructive disease, persistent culture positivity despite an adequate regimen, resistance, substantial hemoptysis or inability to sustain useful medical treatment. Surgery supplements antimicrobial therapy. Assess predicted postoperative reserve, distribution of disease, nutrition, comorbidities and operative expertise.

Balance the potential benefit of resection against operative risk and the distribution of disease. Seek a surgical team experienced in NTM disease.

When cure is not a realistic near-term endpoint

When patients cannot tolerate an effective combination, clarify the goals they most value, such as control of symptoms or preserving function. An NTM specialist can help weigh any further chance of microbiologic response against treatment burden.

Associations between culture conversion and survival are subject to confounding. Neither an observational mortality comparison nor a single successful case proves that a particular regimen prolongs survival.

Sources [5] [4] [6] [7] [1] [26]

NTM rounds reference

Establish disease

Symptoms, compatible imaging, exclusion of mimics and usually two same-species sputum cultures or one wash/BAL. M. abscessus requires the same subspecies.

Choose an endpoint

Treatment or observation, with explicit goals and follow-up. Cavities, smear positivity and progression favor treatment.

MAC

Susceptible MAC: azithromycin, ethambutol, rifamycin. Intermittent for nonsevere noncavitary nodular-bronchiectatic disease. Cavitary or severe disease favors daily therapy. For cavitary, advanced/severe bronchiectatic or macrolide-resistant MAC, the guideline suggests initial parenteral amikacin or streptomycin if activity and toxicity risk permit. ≥12 months after conversion.

M. abscessus

The guideline suggests ≥3 active drugs initially. For inducible or mutational macrolide resistance, the guideline summary suggests ≥4 when feasible. An inactive macrolide does not count.

M. kansasii

Rifampin + ethambutol + isoniazid or macrolide when rifampin-susceptible. At least 12 months total; no pyrazinamide.

Monitoring

Serial cultures, weight, functional status and adherence. Ask about hearing/balance with ototoxic drugs, vision with ethambutol or linezolid, and neuropathy with linezolid or isoniazid.

Extrapulmonary

Deep specimens, species identification and source control. Pulmonary diagnostic and duration rules do not automatically apply.

Apparent failure

Check exposure, susceptibility and toxicity. ALIS is an add-on for adults with few or no alternatives and positive sputum after ≥6 consecutive months of multidrug MAC therapy.

Sources and evidence limits

Adult pulmonary treatment recommendations are principally based on the 2020 multisociety guideline. Extrapulmonary recommendations draw on older guidance and species-specific reports and have less certain treatment durations. Much of the evidence for toxicity surveillance comes from clinical experience rather than comparisons of monitoring strategies.

  1. ATS/ERS/ESCMID/IDSA, 2020. Adult pulmonary NTM treatment guideline. Excludes HIV and cystic fibrosis.
  2. British Thoracic Society, 2017. NTM pulmonary disease guideline, including response monitoring.
  3. Cimino et al., 2024. Pharmacotherapeutic considerations, dosing, interactions and monitoring.
  4. FDA, 2026. ARIKAYCE prescribing information, indication, dose and safety.
  5. Griffith et al., 2018. CONVERT randomized trial in refractory pulmonary MAC.
  6. Zweijpfenning et al., 2024. Randomized clofazimine versus rifampicin trial in pulmonary MAC.
  7. Winthrop et al., 2026. Phase 2 randomized omadacycline trial in M. abscessus pulmonary disease.
  8. ATS/IDSA, 2007. Extrapulmonary species-specific guidance; older evidence with important limitations.
  9. 2022 cohort. Treatment and outcome of culture-confirmed M. marinum disease.
  10. Brown-Elliott et al., 2023. Inducible macrolide resistance in M. chelonae due to erm(55).
  11. NIH. Disseminated MAC in adults and adolescents with HIV, current online guidance.
  12. CDC, 2016. M. chimaera contamination of heater-cooler devices used in cardiac surgery.
  13. CDC. Clinical overview of NTM, specimen collection, healthcare-associated infection and prevention.
  14. Cystic Fibrosis Foundation / European Cystic Fibrosis Society. NTM clinical care recommendations.
  15. 2019. Clinical relevance of NTM isolated from respiratory specimens, seven-year UK hospital cohort.
  16. CDC. Environmental infection control, water-associated NTM and pseudo-outbreaks.
  17. 2016. Bronchoscopy-associated M. gordonae pseudo-outbreak investigation.
  18. Miwa et al., 2014. Preliminary randomized two- versus three-drug pulmonary MAC study.
  19. Im et al., 2025. Outcomes with macrolide plus ethambutol in pulmonary MAC; uncontrolled cohort.
  20. 2023. Linezolid trough exposure and severe toxicity in multidrug-resistant tuberculosis; extrapolation to NTM requires caution.
  21. National Jewish Health. Linezolid level PKLZD, public test directory.
  22. University of Florida IDPL. Current test catalog and requisition resources.
  23. NUZYRA prescribing information, revised May 2026. Oral administration and dosing.
  24. ATS/CDC/ERS/IDSA, 2025. TB treatment update, including linezolid TDM safety guidance; not an NTM efficacy target.
  25. Henkle et al., 2026. MAC2v3 initial results, published ATS meeting abstract.
  26. ENCORE, 2026. Randomized trial of ALIS added to azithromycin and ethambutol in newly diagnosed pulmonary MAC.
  27. US prescribing information for linezolid. Myelosuppression, peripheral and optic neuropathy.
  28. van Ingen et al., 2018. NTM-NET consensus definitions of treatment outcomes.